Key result
Orthotopic heart transplantation can be a viable therapeutic option for patients with arrhythmogenic right ventricular cardiomyopathy, allowing for definitive pathological diagnosis.
Case Report (n=2)
Heart transplantation is a viable therapeutic option for patients with ARVC and provides pathological confirmation of the disease.
May support transplantation in advanced ARVC; leaves open need for larger studies on outcomes and applicability.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a myocardial disease characterized by fibrofatty replacement. The main clinical features are sudden death due to ventricular arrhythmias and congestive heart failure. Diagnosis of ARVC is still problematic and frequently made only by autopsy. Criteria for orthotropic heart transplant (HTx) have still not well been defined. We present two cases of arrhythmogenic right ventricular cardiomyopathy who underwent heart transplant. They demonstrate that heart transplant can be a real therapeutic option for these patients and offer to us the possibility to confirm the diagnosis and better understand pathological and histological features of the disease.
No takes yet. Share an insight, caveat, or question.
GD et al. (2015) conducted a case report in Arrhythmogenic right ventricular cardiomyopathy (ARVC) (n=2). Orthotopic heart transplant was evaluated. Orthotopic heart transplantation can be a viable therapeutic option for patients with arrhythmogenic right ventricular cardiomyopathy, allowing for definitive pathological diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Heart transplantationMore from Journal of Cytology & Histology